← Leaderboards
Ian M Orme
Colorado State University-Fort Collins
$17,908,319
Attributed
$17,908,319
Total exposure
13
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.6M · FY2005–16$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$17,908,319 · 13
By mechanism
R01$9,372,944 · 5
U01$6,420,965 · 1
R21$1,414,299 · 4
N01$445,636 · 1
R03$140,467 · 1
P01$114,008 · 1
Top collaborators
No co-investigators on record.
Most similar at Colorado State University-Fort Collins
Same institution · by research overlap
- Dean C Crick$6,993,235
- Michael R McNeil$4,500,958
- James H Naismith$554,601
- Anne J. Lenaerts$473,542
Others in their field
Top investigators on “Tuberculosis”
- Judith S. Currier · University Of California Los Angeles$301,722,065
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$297,204,160
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$267,912,117
- Lawrence Corey · Fred Hutchinson Cancer Center$255,939,398
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$200,192,298
- Sharon A Nachman · Johns Hopkins University$194,852,226
Research focus
TuberculosisMycobacterium TuberculosisLaboratory MouseTuberculosis VaccinesCytokineBacterial AntigensAerosolsBactericidal ImmunityBaseCytotoxic T LymphocyteAnimal ModelVaccine DevelopmentHistologyLungVirulentVaccinesImmunocytochemistryLaboratoriesVaccinationAnimalsGenus MycobacteriumProgramsHelper T LymphocyteDrug Screening /Evaluation
Grant awards (48)
Novel vaccine boosting candidates for tuberculosis$188,334
R21 · FY2016 · AI · contact PI
BCG efficacy against W-Beijing TB strains$223,050
R21 · FY2015 · AI · contact PI
Environmental mycobacteria and BCG interference$223,050
R21 · FY2015 · AI · contact PI
BCG efficacy against W-Beijing TB strains$185,875
R21 · FY2014 · AI · contact PI
Environmental mycobacteria and BCG interference$185,875
R21 · FY2014 · AI · contact PI
Transcriptional analysis of the guinea pig model of tuberculosis$64,175
R03 · FY2014 · AI · contact PI
Virulence of MDR-TB strains$222,750
R21 · FY2013 · AI · contact PI
Transcriptional analysis of the guinea pig model of tuberculosis$76,292
R03 · FY2013 · AI · contact PI
Virulence of MDR-TB strains$185,365
R21 · FY2012 · AI · contact PI
Response Therapies for MDR-TB$1,259,826
U01 · FY2010 · AI · contact PI
Response Therapies for MDR-TB$1,421,958
U01 · FY2009 · AI · contact PI
Response Therapies for MDR-TB$1,131,873
U01 · FY2008 · AI · contact PI
Chronic Tuberculosis: Latent or Dynamic$302,187
R01 · FY2008 · AI · contact PI
Response Therapies for MDR-TB$1,213,289
U01 · FY2007 · AI · contact PI
Guinea pig model for TB vaccine evaluations$509,881
R01 · FY2007 · AI · contact PI
Chronic Tuberculosis: Latent or Dynamic$308,039
R01 · FY2007 · AI · contact PI
Response Therapies for MDR-TB$1,394,019
U01 · FY2006 · AI · contact PI
Guinea pig model for TB vaccine evaluations$642,082
R01 · FY2006 · AI · contact PI
Chronic Tuberculosis: Latent or Dynamic$317,240
R01 · FY2006 · AI · contact PI
Defined Native Antigens and Immunity to tuberculosis$281,920
R01 · FY2006 · AI · contact PI
Guinea pig model for TB vaccine evaluations$721,424
R01 · FY2005 · AI
Chronic Tuberculosis: Latent or Dynamic$324,874
R01 · FY2005 · AI
Defined Native Antigens and Immunity to tuberculosis$288,704
R01 · FY2005 · AI
Guinea pig model for TB vaccine evaluations$663,727
R01 · FY2004 · AI
Chronic Tuberculosis: Latent or Dynamic$324,874
R01 · FY2004 · AI
STRATEGIES FOR TUBERCULOSIS VACCINE DEVELOPMENT AND SCRE$290,000
R01 · FY2004 · AI
Defined Native Antigens and Immunity to tuberculosis$288,704
R01 · FY2004 · AI
Guinea pig model for TB vaccine evaluations$465,037
R01 · FY2003 · AI
CHRONIC TUBERCULOSIS--LATENT OR DYNAMIC$290,934
R01 · FY2003 · AI
STRATEGIES FOR TUBERCULOSIS VACCINE DEVELOPMENT AND SCRE$290,000
R01 · FY2003 · AI
Defined Native Antigens and Immunity to tuberculosis$288,704
R01 · FY2003 · AI
CHRONIC TUBERCULOSIS--LATENT OR DYNAMIC$305,154
R01 · FY2002 · AI
STRATEGIES FOR TUBERCULOSIS VACCINE DEVELOPMENT AND SCRE$290,000
R01 · FY2002 · AI
Defined Native Antigens and Immunity to tuberculosis$280,604
R01 · FY2002 · AI
AGING AND IMMUNITY IN TUBERCULOSIS$72,500
R01 · FY2002 · AG
CORE--MACROPHAGE AND ANIMAL MODELS, MICS, CYTOTOXICITY FACILITY$0
P01 · FY2002 · AI
CHRONIC TUBERCULOSIS--LATENT OR DYNAMIC$296,266
R01 · FY2001 · AI
STRATEGIES FOR TUBERCULOSIS VACCINE DEVELOPMENT AND SCRE$290,000
R01 · FY2001 · AI
AGING AND IMMUNITY IN TUBERCULOSIS$250,332
R01 · FY2001 · AG
CORE--MACROPHAGE AND ANIMAL MODELS, MICS, CYTOTOXICITY FACILITY$0
P01 · FY2001 · AI
ANIMAL MODEL TESTING OF TB DRUGS$445,636
N01 · FY2000 · AI
STRATEGIES FOR TUBERCULOSIS VACCINE DEVELOPMENT AND SCRE$283,925
R01 · FY2000 · AI
AGING AND IMMUNITY IN TUBERCULOSIS$243,042
R01 · FY2000 · AG
CHRONIC TUBERCULOSIS--LATENT OR DYNAMIC$223,468
R01 · FY2000 · AI
DEFINED NATIVE ANTIGENS AND IMMUNITY TO TUBERCULOSIS$217,291
R01 · FY2000 · AI
CORE--MACROPHAGE AND ANIMAL MODELS, MICS, CYTOTOXICITY FACILITY$114,008
P01 · FY2000 · AI
CHRONIC TUBERCULOSIS--LATENT OR DYNAMIC$22,031
R01 · FY2000 · AI
ANIMAL MODEL TESTING OF TB DRUGS$0
N01 · FY2000 · AI